Margetuximab
Based on 1 Customer Validation
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer.
For research use only. We do not sell to patients.
- Purity: ≥99.0%
- CAS No.: 1350624-75-7
- Molecular Weight:146.1 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All EGFR Isoforms
More
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
ERBB2/HER2/CD340
In Vitro
Margetuximab (MGAH22) enhances the antibody-dependent cell-mediated cytotoxicity activity of effector cells expressing the CD16A-158F variant[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:JIMT-1, MCF-7, ZR-75-1, SKBR-3, HT-29, SW750 and N87[1]
-
Concentration:0.001-1000 ng/mL
-
Incubation Time:6 days
-
Result:Enhances the antibody-dependent cell-mediated cytotoxicity activity of effector cells expressing the CD16A-158F variant.
In Vivo
| Male, IV (50 mg/kg) | Female, IV (50 mg/kg) | |
| Cmax (mg/mL) | 1.62 ± 0.10 | 1.70 ± 0.14 |
| AUC0-¥ (mg·hour/mL) | 294.1 ± 53.2 | 314.2 ± 31.3 |
| T1/2β (days) | 9.3 ± 1.8 | 9.7 ± 1.1 |
| Clearance (mL/hour) | 0.43 ± 0.07 | 0.40 ± 0.04 |
| VSS (mL) | 132 ± 2 | 127 ± 8 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Loaded Margetuximab on AHC2 biosensor, can bind HER2/CD340 Protein, Human (HEK293, His, HY-P70254) with an affinity constant of 5.604E-10 M as determined in BLI assay. -
Flow cytometric analysis of 1X106 MCF-7 cells with Margetuximab (HY-P99030, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1350624-75-7
-
Appearance Liquid
-
Molecular Weight 146.1 kDa
-
Color Colorless to light yellow
-
SMILES
[Margetuximab]
-
Synonyms
MGAH-22
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)